<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href="https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm Q is one of the treatment sub-protocols within the <a href="https://clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;draw=2&#x26;rank=1">NCI-MATCH Clinical Trial (EAY131)</a> where patients with HER2 amplification are treated with Kadcyla<sup>®</sup> (ado-trastuzumab emtansine). This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including tumor tissue and whole blood.</p>

Genomic Characterization CS-MATCH-0007 Arm Q

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

The NCI-MATCH trial: lessons for precision oncology

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.